Published in Vaccine Weekly, May 13th, 1996
Several attenuated RSV subgroup A mutants hold promise as vaccine candidates, but they are not likely to offer cross-protection against RSV subgroup B viruses.
Now researcher James E. Crowe Jr. and colleagues at the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, have created cpts-176: a stable, multiply attenuated RSV subgroup B virus that is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly